JP2016522211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522211A5 JP2016522211A5 JP2016516825A JP2016516825A JP2016522211A5 JP 2016522211 A5 JP2016522211 A5 JP 2016522211A5 JP 2016516825 A JP2016516825 A JP 2016516825A JP 2016516825 A JP2016516825 A JP 2016516825A JP 2016522211 A5 JP2016522211 A5 JP 2016522211A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pcsk9
- antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828730P | 2013-05-30 | 2013-05-30 | |
| US61/828,730 | 2013-05-30 | ||
| US201361889553P | 2013-10-11 | 2013-10-11 | |
| US61/889,553 | 2013-10-11 | ||
| US201361901212P | 2013-11-07 | 2013-11-07 | |
| US61/901,212 | 2013-11-07 | ||
| PCT/US2014/040050 WO2014194111A1 (en) | 2013-05-30 | 2014-05-29 | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522211A JP2016522211A (ja) | 2016-07-28 |
| JP2016522211A5 true JP2016522211A5 (enExample) | 2017-06-22 |
| JP6423868B2 JP6423868B2 (ja) | 2018-11-14 |
Family
ID=51205567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516825A Active JP6423868B2 (ja) | 2013-05-30 | 2014-05-29 | Ｐｃｓｋ９機能獲得型変異に関連する常染色体優性高コレステロール血症を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140356370A1 (enExample) |
| EP (1) | EP3004172B1 (enExample) |
| JP (1) | JP6423868B2 (enExample) |
| KR (1) | KR20160013046A (enExample) |
| CN (2) | CN113144195A (enExample) |
| AU (1) | AU2014274077B2 (enExample) |
| CA (1) | CA2912101A1 (enExample) |
| EA (1) | EA201592304A1 (enExample) |
| IL (1) | IL242251B (enExample) |
| TW (1) | TWI682780B (enExample) |
| WO (1) | WO2014194111A1 (enExample) |
| ZA (1) | ZA201507798B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| ES2914978T3 (es) * | 2013-10-11 | 2022-06-20 | Sanofi Biotechnology | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| WO2016100615A2 (en) * | 2014-12-18 | 2016-06-23 | The University Of Chicago | Methods and composition for neutralization of influenza |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| JP7102401B2 (ja) | 2016-10-25 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーデータ解析のための方法およびシステム |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP7050807B2 (ja) | 2017-04-13 | 2022-04-08 | カディラ ヘルスケア リミティド | 新規ペプチドベースのｐｃｓｋ９ワクチン |
| AU2018291702A1 (en) * | 2017-06-30 | 2020-02-06 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising PCSK-9 antibody and use thereof |
| CA3073935A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| IL319165A (en) | 2017-12-13 | 2025-04-01 | Regeneron Pharma | Apparatus and methods for managing support of a chromatography column substrate and related methods |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| IL292973B2 (en) * | 2019-11-18 | 2026-03-01 | Ad Pharmaceuticals Co Ltd | Anti-PCSK9 antibody and its use |
| WO2021119321A1 (en) | 2019-12-10 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
| CN116171161A (zh) | 2020-08-25 | 2023-05-26 | 雷杰纳荣制药公司 | 用pcsk9和ldlr调节剂治疗败血症 |
| CN116189765B (zh) * | 2023-02-23 | 2023-08-15 | 上海捷易生物科技有限公司 | 一种iPS细胞遗传学风险评估系统及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1471152A1 (en) * | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| AR088782A1 (es) * | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) * | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
-
2014
- 2014-05-28 TW TW103118526A patent/TWI682780B/zh not_active IP Right Cessation
- 2014-05-29 EP EP14739600.6A patent/EP3004172B1/en active Active
- 2014-05-29 KR KR1020157033966A patent/KR20160013046A/ko not_active Ceased
- 2014-05-29 CN CN202110182897.4A patent/CN113144195A/zh active Pending
- 2014-05-29 US US14/290,462 patent/US20140356370A1/en not_active Abandoned
- 2014-05-29 JP JP2016516825A patent/JP6423868B2/ja active Active
- 2014-05-29 WO PCT/US2014/040050 patent/WO2014194111A1/en not_active Ceased
- 2014-05-29 EA EA201592304A patent/EA201592304A1/ru unknown
- 2014-05-29 CA CA2912101A patent/CA2912101A1/en not_active Abandoned
- 2014-05-29 CN CN201480031344.7A patent/CN105263963B/zh active Active
- 2014-05-29 AU AU2014274077A patent/AU2014274077B2/en not_active Ceased
-
2015
- 2015-10-19 ZA ZA2015/07798A patent/ZA201507798B/en unknown
- 2015-10-25 IL IL242251A patent/IL242251B/en not_active IP Right Cessation
-
2019
- 2019-03-28 US US16/367,795 patent/US20190330371A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522211A5 (enExample) | ||
| JP2016520616A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| Cicero et al. | on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP)(2020) Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis | |
| Sun et al. | Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis | |
| JP2016538277A5 (enExample) | ||
| JP2018523684A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| Rommer et al. | Monoclonal antibodies in treatment of multiple sclerosis | |
| JP2016538248A5 (enExample) | ||
| Li et al. | Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study | |
| JP2019514907A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| JP2019531273A5 (enExample) | ||
| FI3416684T3 (fi) | Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria | |
| JP2015514110A5 (enExample) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016515134A5 (enExample) | ||
| Katsiki et al. | High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? | |
| JP2017533191A5 (enExample) | ||
| Duggan et al. | Immune modulation to treat Alzheimer’s disease | |
| JP2017533220A5 (enExample) | ||
| JP2019525772A5 (enExample) | ||
| Afkhami et al. | Advancing immunotherapeutic vaccine strategies against pulmonary tuberculosis | |
| Jones et al. | Intravenous immunoglobulin G suppresses heat shock protein (HSP)-70 expression and enhances the activity of HSP90 and proteasome inhibitors |